These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 29606353)

  • 1. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch.
    Liu N; Hargreaves VV; Zhu Q; Kurland JV; Hong J; Kim W; Sher F; Macias-Trevino C; Rogers JM; Kurita R; Nakamura Y; Yuan GC; Bauer DE; Xu J; Bulyk ML; Orkin SH
    Cell; 2018 Apr; 173(2):430-442.e17. PubMed ID: 29606353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription factor competition at the γ-globin promoters controls hemoglobin switching.
    Liu N; Xu S; Yao Q; Zhu Q; Kai Y; Hsu JY; Sakon P; Pinello L; Yuan GC; Bauer DE; Orkin SH
    Nat Genet; 2021 Apr; 53(4):511-520. PubMed ID: 33649594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional Repressor BCL11A in Erythroid Cells.
    Zheng G; Orkin SH
    Adv Exp Med Biol; 2024; 1459():199-215. PubMed ID: 39017845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.
    Sankaran VG; Menne TF; Xu J; Akie TE; Lettre G; Van Handel B; Mikkola HK; Hirschhorn JN; Cantor AB; Orkin SH
    Science; 2008 Dec; 322(5909):1839-42. PubMed ID: 19056937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
    Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
    Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of adult levels of β-globin in human erythroid cells that intrinsically express embryonic or fetal globin by transduction with KLF1 and BCL11A-XL.
    Trakarnsanga K; Wilson MC; Lau W; Singleton BK; Parsons SF; Sakuntanaga P; Kurita R; Nakamura Y; Anstee DJ; Frayne J
    Haematologica; 2014 Nov; 99(11):1677-85. PubMed ID: 25107887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
    Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
    Elife; 2022 Feb; 11():. PubMed ID: 35147495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.
    Lulli V; Romania P; Morsilli O; Cianciulli P; Gabbianelli M; Testa U; Giuliani A; Marziali G
    PLoS One; 2013; 8(4):e60436. PubMed ID: 23593217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
    Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
    Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
    Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
    Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
    Bauer DE; Orkin SH
    Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin genetics: recent contributions of GWAS and gene editing.
    Smith EC; Orkin SH
    Hum Mol Genet; 2016 Oct; 25(R2):R99-R105. PubMed ID: 27340226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.
    Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM
    Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human globin knock-in mice complete fetal-to-adult hemoglobin switching in postnatal development.
    McConnell SC; Huo Y; Liu S; Ryan TM
    Mol Cell Biol; 2011 Feb; 31(4):876-83. PubMed ID: 21173165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional silencing of fetal hemoglobin by BCL11A.
    Sankaran VG; Xu J; Orkin SH
    Ann N Y Acad Sci; 2010 Aug; 1202():64-8. PubMed ID: 20712774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal β-like globin genes.
    Roosjen M; McColl B; Kao B; Gearing LJ; Blewitt ME; Vadolas J
    FASEB J; 2014 Apr; 28(4):1610-20. PubMed ID: 24371119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.
    Masuda T; Wang X; Maeda M; Canver MC; Sher F; Funnell AP; Fisher C; Suciu M; Martyn GE; Norton LJ; Zhu C; Kurita R; Nakamura Y; Xu J; Higgs DR; Crossley M; Bauer DE; Orkin SH; Kharchenko PV; Maeda T
    Science; 2016 Jan; 351(6270):285-9. PubMed ID: 26816381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.